Presentation

Navamedic is a Norwegian pharma company headquartered in Oslo with a footprint in Northern Europe. Navamedic has four business segments – Specialty Pharma, Medical Nutrition, Branded Generics, and Consumer Health, with product portfolio consisting of Rx and OTC pharmaceuticals and other healthcare products registered as medical nutrition and medical devices, food supplements or cosmetics. Navamedic is present in all Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece.

Recent highlights
The company delivered record high Q2 revenue of 110.4M NOK (+67%) and EBITDA of 23.7M NOK (+451%), resulting from a strong growth across several key products, particularly the obesity drug Mysimba.
In May, Navamedic acquired Impolin AB, a Swedish-based distributor, to expand its product portfolio for obesity treatment. Navamedic plans to launch Impolin’s product Modifast in Norway, Finland and Denmark during the coming 12-24 months. In August, Navamedic signed an agreement with Vectans Pharma, which gives Navamedic the exclusive right to market and sell Sitavig®, an innovative muco-adhesive buccal tablet for single-dose treatment of cold sores in the Nordic and Benelux regions.

Outlook
The mid-term ambition of the company is 20% annual organic growth and to build a NOK 1 billion revenue company including M&A with a gross margin of at least 40% and an EBITDA margin of 15%.